TY - JOUR
T1 - The impact of weight loss on physical function and symptoms in overweight or obese breast cancer survivors
T2 - results from POWER-remote
AU - Sheng, Jennifer Y.
AU - Santa-Maria, Cesar A.
AU - Blackford, Amanda L.
AU - Lim, David
AU - Carpenter, Ashley
AU - Smith, Karen L.
AU - Cohen, Gary I.
AU - Coughlin, Janelle
AU - Appel, Lawrence J.
AU - Stearns, Vered
AU - Snyder, Claire
N1 - Publisher Copyright:
© 2021, The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
PY - 2022/6
Y1 - 2022/6
N2 - Purpose: In pre-planned observational analysis of the POWER-remote trial, we examined the impact of weight loss on patient-reported outcomes (PROs). We hypothesized a priori that survivors with ≥ 5% weight loss would have improved physical function (PF) at 6 months vs. those who did not. Methods: Patients with stage 0-III breast cancer who completed local therapy and chemotherapy with BMI ≥ 25 kg/m2 were randomized to POWER-remote (telephone coaching; diet/activity tracking) or self-directed weight loss (booklet). Participants completed PROs at baseline, 6, and 12 months: PROMIS PF, pain, fatigue, anxiety, depression, sleep; FACT-endocrine symptoms; MOS-sexual function. Changes in PROs among those with ≥ 5% weight loss vs. those with < 5% were tested with multivariable mixed effect models, across randomized groups. Results: Of 94 women who completed PROs, 84 and 69 participants were evaluable at 6 and 12 months, respectively. Regardless of intervention, PF improved in those with ≥ 5% weight loss vs. those with < 5% at 6 months (4.4 vs. 0.3 points; p = 0.02) and 12 months (3.6 vs. 0 points; p = 0.04). While endocrine symptoms, fatigue, and anxiety improved at 6 months in those who lost ≥ 5%, differences were not significant vs. those who lost < 5%. There was no significant change within or between groups in sexual function, depression, or sleep. Findings at 12 months were similar, except pain improved in those losing ≥ 5%. Conclusions: These results support the benefits of weight loss in overweight/obese breast cancer survivors. Implications for Cancer survivors: Weight management in breast cancer survivors may improve PF.
AB - Purpose: In pre-planned observational analysis of the POWER-remote trial, we examined the impact of weight loss on patient-reported outcomes (PROs). We hypothesized a priori that survivors with ≥ 5% weight loss would have improved physical function (PF) at 6 months vs. those who did not. Methods: Patients with stage 0-III breast cancer who completed local therapy and chemotherapy with BMI ≥ 25 kg/m2 were randomized to POWER-remote (telephone coaching; diet/activity tracking) or self-directed weight loss (booklet). Participants completed PROs at baseline, 6, and 12 months: PROMIS PF, pain, fatigue, anxiety, depression, sleep; FACT-endocrine symptoms; MOS-sexual function. Changes in PROs among those with ≥ 5% weight loss vs. those with < 5% were tested with multivariable mixed effect models, across randomized groups. Results: Of 94 women who completed PROs, 84 and 69 participants were evaluable at 6 and 12 months, respectively. Regardless of intervention, PF improved in those with ≥ 5% weight loss vs. those with < 5% at 6 months (4.4 vs. 0.3 points; p = 0.02) and 12 months (3.6 vs. 0 points; p = 0.04). While endocrine symptoms, fatigue, and anxiety improved at 6 months in those who lost ≥ 5%, differences were not significant vs. those who lost < 5%. There was no significant change within or between groups in sexual function, depression, or sleep. Findings at 12 months were similar, except pain improved in those losing ≥ 5%. Conclusions: These results support the benefits of weight loss in overweight/obese breast cancer survivors. Implications for Cancer survivors: Weight management in breast cancer survivors may improve PF.
KW - Breast cancer
KW - Obesity
KW - Patient reported outcomes
KW - Physical function
UR - http://www.scopus.com/inward/record.url?scp=85106059477&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85106059477&partnerID=8YFLogxK
U2 - 10.1007/s11764-021-01049-z
DO - 10.1007/s11764-021-01049-z
M3 - Article
C2 - 34018096
AN - SCOPUS:85106059477
SN - 1932-2259
VL - 16
SP - 542
EP - 551
JO - Journal of Cancer Survivorship
JF - Journal of Cancer Survivorship
IS - 3
ER -